Flagship Pioneering launched a new company called Inzen Therapeutics, which will discover and develop a new class of medicines based on a new area of biology that will provide new therapeutic approaches to multiple types of diseases.
If you are not happy with the results below please do another search
50 search results for:
Fishawack Health, a leading global commercialization partner for the life sciences industry, announced the acquisition of StoneArch, a Minneapolis-based healthcare marketing agency renowned for strategic, creative and storytelling capabilities.
The U.S. Food and Drug Administration accepted for priority review a Biologics License Application (BLA) for Merck’s 15-valent pneumococcal conjugate vaccine V114.
Moncef Slaoui, the GlaxoSmithKline vaccines veteran who has helmed the federal government’s Operation Warp Speed Covid-19 vaccine program, is stepping down from the role ahead of the inauguration of President-elect Joe Biden.
The second year of the Covid-19 pandemic may be tougher than the first given how the new coronavirus is spreading, especially in the northern hemisphere as more-infectious variants circulate, the World Health Organization (WHO) said.
Amgen is partnering with Ann Arbor, Michigan-based EVOQ Therapeutics for a license and collaboration deal to discover and develop drugs for autoimmune disorders.
U.S. firm Johnson & Johnson is likely to apply for EU approval for the company’s Covid-19 vaccine candidate in February, a top lawmaker said.
China’s Sinovac Biotech defended the safety and efficacy of the company’s experimental Covid-19 vaccine, after researchers in Brazil released late-stage clinical data showing efficacy that was much lower than initially announced.
In this webinar, you will hear from the Kline Group about a trend moving into dietary supplements, and from Catalent about how supplement brands are accelerating toward a more natural, plant–based portfolio, including in the ever–important heart health market.
At the 2021 virtual JP Morgan Healthcare Conference, Vertex Pharmaceuticals’ chief executive officer Reshma Kewalramani said the company is looking to buy “mid- and late-stage assets.”